Highlights
1 patent
About
Enzymatic Therapeutics for Non-Surgical Tissue Repair
MediWound is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.
Identity
| Name | MediWound |
|---|---|
| Slug | mediwound |
| Type / kind | startup |
| Crunchbase ID | mediwound |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ7f8PILDA |
Status
| Status | active |
|---|---|
| Status reason | Public on NASDAQ on Mar, 2014; |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Yavne |
| HQ address | 42 Hayarkon Street, Yavne, Israel |
Web & social
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business models
B2B2C
Tags
tissue-regenerationdermatologyburnsbiotechnologytopical-treatmentpatientspharma-companiespharmaceuticals
Funding
| Total raised | $198.7M |
|---|---|
| Current stage | Public |
| Market cap | $236.7M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}